According to the World Health Organization, over 350 million people worldwide are suffering from depression. Although current medical treatments can help, their troublesome side effects and incomplete therapeutic effects mean that they are not nearly good enough to cure the disease outright. These people deserve better. At One Mind Institute, we believe cures for depression are not just necessary but possible, and we are committed to funding the hunt.
Today, scientists funded by One Mind Institute have made a raft of tremendous advances in our understanding and potential to treat depression. For example, Dr. Scott Russo’s newly developed understanding of the relationship between depression and the immune system has enabled him to partner with Johnson & Johnson to start to develop two new medications to treat the disease. Dr. Stephanie Dulawa is investigating a molecular mechanism to which a future class of fast-acting antidepressant medications can be targeted—in mice, she has shown related compounds to relieve depression-like behaviors in five days versus the current three-week benchmark.
“Brain diseases really get to the heart of who we are as human beings,” says One Mind Institute funded scientist Dr. Vikaas Sohal. “How we feel, and how we relate to the world and to other people. So, of course we want to help everybody function as best they can.”